Development of Chimeric Antigen Receptor-Expressing iPSC-Derived Macrophages with Improved Anti-Tumor Activity

被引：3

作者：

Pouyanfard, Somayeh ^{[1
]}

Fierro, Manuel ^{[1
]}

Skaufman, Dan ^{[1
]}

机构：

[1] Univ Calif San Diego, Div Regenerat Med, Dept Med, La Jolla, CA USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-148687

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1693

引用

页数：3

共 50 条

[31] FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3
Zorko, Nicholas
Cichocki, Frank
Goulding, John
Hancock, Bryan
Blum, Robert
Pribadi, Mochtar
Gaertner, Bjoern
Lee, Tom
Felices, Martin
Bjordahl, Ryan
Valamehr, Bahram
Miller, Jeffrey S.
CANCER RESEARCH, 2022, 82 (12)
[32] Notch Activation Rescues Exhaustion in CISH-Deleted Hum iPSC-Derived Natural Killer Cells to Promote In Vivo Persistence and Enhance Anti-Tumor Activity
Zhu, Huang
Blum, Robert
Wu, Zhengming
Bahena, Andres
Hoel, Hanna Julie
Ask, Eivind Heggernes
Guan, Kun-Liang
Malmberg, Karl-Johan
Kaufman, Dan S.
BLOOD, 2018, 132
[33] Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells
Stach, Martin
Ptackova, Pavlina
Mucha, Martin
Musil, Jan
Klener, Pavel
Otahal, Pavel
CYTOTHERAPY, 2020, 22 (12) : 744 - 754
[34] Chimeric Antigen Receptor Macrophages (CAR-M) Induce Anti-Tumor Immunity and Synergize with Immune Checkpoint Inhibitors in Pre-Clinical Solid Tumor Models
Pierini, Stefano
Gabbasov, Rashid
Worth, Alison
Gabitova, Linara
Blumenthal, Daniel
Ohtani, Yumi
Shestova, Olga
Shestov, Maksim
Gill, Saar
Abramson, Sascha
Condamine, Thomas
Klichinsky, Michael
MOLECULAR THERAPY, 2021, 29 (04) : 74 - 74
[35] Short-term cytolytic assays are not predictive of chimeric antigen receptor anti-tumor activity mediated by some T cell subsets
Lin, Tasha L.
Lee, Daniel W.
Kochenderfer, James N.
Mackall, Crystal L.
CANCER RESEARCH, 2012, 72
[36] PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
Wei, Jianshu
Luo, Can
Wang, Yao
Guo, Yelei
Dai, Hanren
Tong, Chuan
Ti, Dongdong
Wu, Zhiqiang
Han, Weidong
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
[37] High affinity NK cells expressing a PD-L1 chimeric antigen receptor demonstrate anti-tumor activity in head and neck cancer through multiple distinct mechanisms
Robbins, Yevtte
Friedman, Jay
Greene, Sarah
Fabian, Kellsye
Padget, Michelle
Lee, John
Soon-Shiong, Patrick
Niazi, Kayvan
Sender, Lennie
Boissel, Laurent
Schlom, Jeffrey
Hodge, James
Allen, Clint
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[38] Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape
Yang, Bi-Huei
Lin, Yu-Sheng Eason
Shirinbak, Soheila
Yeh, Wen-I
Pribadi, Mochtar
Chu, Hui-Yi
Gutierrez, Alma
Mehta, Amit
Avramis, Earl
Petrovic, Roseanna
Whitlock, Benjamin
ORourke, Jason
van der Stegen, Sjoukje
Lee, Tom
Witty, Alec
Peralta, Eigen
Hosking, Martin
Chang, Chia-Wei
Valamehr, Bahram
BLOOD, 2021, 138
[39] Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells
Fanyi Meng
Siqi Zhang
Juan Xie
Yuan Zhou
Qingling Wu
Binyan Lu
Shixin Zhou
Xiangyu Zhao
Yang Li
Journal of Hematology & Oncology, 16
[40] Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12
Chi, Xiaowei
Yang, Peiwei
Zhang, Erhao
Gu, Jieyi
Xu, Hui
Li, Mengwei
Gao, Xinmei
Li, Xin
Zhang, Yinan
Xu, Hanmei
Hu, Jialiang
CANCER MEDICINE, 2019, 8 (10): : 4753 - 4765

← 1 2 3 4 5 →